( ALISO VIEJO Calif.--(BUSINESS WIRE)--J...)AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain,Health

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced the presentation of Phase III data, including efficacy, safety and improvements in patient-centered outcomes in patients with diabetic peripheral neuropathic (DPN) pain treated with the investigational drug Zenvia(TM) (dextromethorphan/quinidine (DM/Q)), an NMDA receptor antagonist and sigma-1 agonist. The data were accepted as 'late-breakers' and presented in two posters at the Second International Congress on Neuropathic Pain (ICNP) in Berlin.

DPN pain is a common complication of diabetes that has significant impact on outcomes of concern to patients including sleep, activity and quality of life. In a multi-center, 3-month, double-blind Phase III trial, active treatment with Zenvia 45/30 mg dosed twice daily (DM/Q 45) and 30/30 mg DM/Q dosed twice daily (DM/Q 30) over a three month period, was compared to placebo. AVANIR previously announced in April 2007 that both doses of Zenvia had met the primary endpoint of statistically significant improvements versus placebo as recorded in daily patient diary entries using the Pain Rating Scale, as defined in the Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). In addition the DM/Q 45 met statistical significance for 4 out of 5 secondary endpoints reported.

Highlights of new Zenvia data presented at ICNP:

-- DM/Q 45 achieved 53%, 59% and 59% improvement versus baseline, DM/Q 30 achieved 43%, 48% and 48% improvement and placebo achieved 27%, 34% and 39% improvement at days 30, 60 and 90, respectively in the Pain Rating Scale.

-- 28% of patients in the DM/Q 45 arm and 27% in the DM/Q 30 arm obtained "a lot" of or "complete" pain relief at three months versus 17% in the placebo group (p=0.0008 and p=0.0017 respectively)

-- Active treatment with both Zenvia doses significantly reduced pain interference with
'"/>

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at Second International Congress on Neuropathic Pain
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies